Modular scientific content and review in Medical Affairs Omnichannel

A Medical Affairs team supporting a medicine with new phase three data needs that data in a liaison slide deck, a medical information standard response, a congress booth panel, a scientific webinar and a page on the medical portal. In most companies each of these is written by a different person, reviewed as a separate item and approved on a different date. The HCP who meets three of them sees three slightly different accounts of the same trial. The team that produced them spent five review cycles on one set of facts.

Modular content is the response most companies are now pursuing. This article describes what it means in a Medical setting, what has to be true for it to work, and how the review process has to change. It does not describe a content model or a tagging scheme, which differ by company and platform.

What is modular content in Medical Affairs?

It is scientific content approved in reusable units. A unit might be a statement of a trial's primary endpoint with its reference, a figure showing a safety result, or a paragraph on a mechanism of action. Each unit is reviewed and approved once. A liaison deck, a standard response and a portal page are then assembled from approved units, and the assembly is checked for context and balance, which is a lighter review than approving the science again.

The approach came from commercial content operations, and Medical teams are right to be cautious about importing it unchanged. Scientific content depends on context more than promotional content does. A result presented without its limitations, or a subgroup finding without the primary analysis, can mislead even when each unit is accurate. Modular content in Medical needs rules about which units must travel together.

Why does Medical Omnichannel engagement need it?

Because consistency across touch points is what HCPs experience as quality. An HCP who discusses a study with a liaison, receives a written response from medical information and later opens a portal page should find the same science in each. That is achievable when all three draw on the same approved units. It is very hard to achieve when each is written independently. The Medical Affairs Professional Society's guidance and IQVIA's paper on Medical Affairs Omnichannel both identify content as a constraint on Medical Omnichannel engagement.

Speed is the second reason. Digital channels in Medical often launch with little content because each piece waits in a review queue. Units already approved for a liaison deck can serve a portal page within days.

What has to be true for it to work?

• One owner for the science. A named Medical owner is accountable for each unit and for updating it when data change. In many companies medical information or scientific communications already holds this role for standard responses, and extending it is easier than creating a new one.
• Rules for assembly. Medical, Legal and Compliance agree which units must appear together, which may stand alone and which channels each may be used in. These rules protect balance and context.
• A review designed for Medical. Non-promotional scientific content is reviewed against scientific accuracy, balance and the rules on scientific exchange under the EFPIA Code and the IFPMA Code of Practice. A process built for promotional claims asks different questions and takes longer.
• Maintenance of the library. Units are retired or updated when a label changes, new data are published or a reference is superseded. A library nobody maintains becomes a compliance risk within a year.
• Records of use. The company can show which units were used where and when, which is what an audit will ask.

How does the review process change?

It moves earlier and becomes two-tiered. The substantial review happens once, at the level of the unit, with scientific, legal and compliance reviewers examining the statement and its evidence. The second review, at the level of the assembled piece, checks that the rules for assembly were followed and that the piece suits its channel. Teams that make this change report shorter cycles and fewer disagreements, because the science is settled before the format is discussed.

Medical should own its review path. Where Medical content shares a queue and a committee with promotional material, scientific answers wait behind campaign assets, and reviewers apply promotional reasoning to non-promotional content. A separate path with reviewers who understand scientific exchange is a clear improvement a Medical leader can make.

What are the warning signs?

• Several versions of one summary. Liaison, medical information and digital teams each hold their own account of the same study.
• One queue for everything. Medical content is reviewed with promotional material, by the same committee, to the same checklist.
• A library without an owner. Units were approved once and have not been reviewed since the label changed.
• Digital channels without content. The portal launched months ago and carries a fraction of what liaisons present.
• Units used out of context. A result appears in a channel without the limitations that accompanied it at approval.

Where should a Medical Affairs team begin?

With one study and the questions HCPs ask about it. Take the content that already exists across the liaison deck, the standard responses and any digital material, and compare the versions. The differences make the case for a single set of approved units. Agree the rules for assembly with Legal and Compliance for that one study, set up the two-tier review and measure the cycle time against the previous one. A single study handled this way gives Medical leadership the evidence to extend the approach.